Our very own Dr. Michael J. Endl was the first surgeon in upstate New York to perform the Hydrus Microstent procedure for glaucoma. A number of minimally-invasive surgical techniques have been introduced as a treatment to prevent glaucoma from progressing; ab interno trabecular bypass surgery with the Schlemm's canal Hydrus microstent is one of them.Few adverse events were found in either group. You visualize the entire implantation process. The stent is made of inactive titanium and will allow fluid to leave your eye. The Hydrus Microstent is a revolutionary new therapy used during cataract surgery to help manage your glaucoma. Q1. with the Hydrus microstent implanted during cataract surgery and cataract surgery alone. Its design allows for continued dilation of and maximum aqueous flow through Schlemm’s canal – reducing intraocular pressure for patients with mild to moderate primary open-angle glaucoma.In addition to the HORIZON trial, the Hydrus Microstent has been examined in various national and international studies with both stand-alone glaucoma procedures and cataract-glaucoma procedures. 16 At 24 months, more patients in the Hydrus group had at least 20% reduction in washed out diurnal IOP than that in the control group (80% vs 46%; P = 0.0008). The study found that the Hydrus microstent nearly doubled the number of people not using IOP lowering medication at one year, from about a quarter to almost a half; this evidence was of low-certainty, because of problems with study quality and the small number of participants. Most payers, including Medicare and the large insurance companies, have approved it.The ease of placement of the Hydrus Microstent makes this device much more user-friendly than one might expect.
When we get more aggressive with our operations, however, the conversation gets more involved, and we have to tell patients, “Well, your vision might be blurry for a while, because your pressure might be transiently too low, or there might be some bleeding and some time needed for the blood to clear postoperatively.” That discussion increases chair time. Canal stenting: Into Schlemm’s and beyond. We can track results per surgeon, and we can track patients who underwent surgery elsewhere to see if low pressures are being maintained over time. At the 24-month follow-up visit, mean IOPs were 16.9 ± 3.3 mmHg in the Hydrus/PE/IOL study arm and
It has been proven in global clinical trials to lower eye pressure, which resulted in a reduction of glaucoma medicine and, … To have these safer options has been game-changing.Delivering a New Confidence with the Hydrus MicrostentAlthough we are comparing data from two different studies, the patients enrolled were similar in terms of demographics and their glaucoma status, and they all had cataract surgery. It looks like a large device that must go in a very small space. Its design allows for continued dilation of and maximum aqueous flow through Schlemm’s canal – reducing intraocular pressure for patients with … When stenting the canal is an option, it is a quick discussion.Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated.We do a fair amount of comanagement, and the first month after cataract surgery in a patient with glaucoma was always a little rocky. The Hydrus II prospective study randomized OAG patients to receive Hydrus microstent combined with cataract surgery (n = 50) or cataract surgery alone (n = 50).